Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer

Ong, WL; Evans, M; Papa, N; Williams, S; Millar, J

Author(s): Ong, WL; Evans, M; Papa, N; Williams, S; Millar, J;
Details: Publication Year 2023-10,Volume 67,Issue #7,Page 789-795
Journal Title: Journal of Medical Imaging and Radiation Oncology
Publication Type: Research article
Abstract: INTRODUCTION: To evaluate patient reported quality of life outcomes (QoL) following low-dose-rate brachytherapy (LDR-BT) and high-dose-rate brachytherapy (HDR-BT) monotherapy for prostate cancer at a population-based setting. METHODS: The study comprised men with low-intermediate risk prostate cancer in the Prostate Cancer Outcomes Registry Victoria (PCOR-Vic), who were treated with LDR-BT or HDR-BT monotherapy between 2015 and 2020 and completed the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire 12-month post-treatment. Men who had ADT were excluded (n = 12). Differences in substantial symptoms (i.e. 'moderate' or 'big' problem on a 5-point Likert scale) between LDR-BT and HDR-BT arms were evaluated using Pearson's chi-squared test. Multivariable linear regressions were used to estimate differences in EPIC-26 urinary, bowel and sexual functional domain scores between LDR-BT and HDR-BT arms. RESULTS: Overall, 198 men were included in this study, of which 167 (84%) had LDR-BT and 31 (16%) had HDR-BT. 9 (4.6%), 10 (5.1%) and 56 (28%) reported substantial symptoms for overall urinary, bowel and sexual function at 12-month post-treatment, with no significant difference between LDR-BT and HDR-BT arms. The adjusted mean differences in urinary incontinence, urinary obstructive, bowel and sexual function domain scores between LDR-BT and HDT-BT were: -3.53 (-8.21 to 1.14), -1.27 (-6.88 to 4.35), -0.01 (-5.63 to 5.63) and -8.68 (-21.44 to 4.07) respectively - these were not statistically significant and did not meet the minimal clinically important difference. CONCLUSION: This is the first Australian population-based study comparing QoL in men who had LDR-BT and HDR-BT, with no statistically or clinically significant differences in QoL observed at 12-month post-treatment.
Publisher: Wiley
Keywords: Male; Humans; Quality of Life; Radiotherapy Dosage; *Brachytherapy; Australia; *Prostatic Neoplasms/radiotherapy; Patient Reported Outcome Measures; brachytherapy; prostate cancer; registry
Department(s): Radiation Oncology
PubMed ID: 37828817
Publisher's Version: https://doi.org/10.1111/1754-9485.13596
Open Access at Publisher's Site: https://doi.org/10.1111/1754-9485.13596
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-12-05 12:35:37

Last Modified: 2023-12-05 12:50:03